Page 47 - Haematologica March 2020

HISTORY, a plasminogen deficiency registry
Schwarzfischer F. Further evidence of a silent plasminogen (PLG) allele in two pater- nity cases. Z Rechtsmed. 1988;101(2):99- 104.
10. Mehta R, Shapiro AD. Plasminogen defi- ciency. Haemophilia. 2008;14(6):1261-1268.
11. Schuster V, Seregard S. Ligneous conjunctivi-
tis. Surv Ophthalmol. 2003;48(4):369-388.
12. Klammt J, Kobelt L, Aktas D, et al. Identification of three novel plasminogen (PLG) gene mutations in a series of 23 patients with low PLG activity. Thromb
Haemost. 2011;105(3):454-460.
13. Tefs K, Gueorguieva M, Klammt J, et al.
Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients. Blood. 2006;108(9):3021-3026.
14. Shapiro AD, Nakar C, Parker JM, et al. Plasminogen replacement therapy for the treatment of children and adults with con- genital plasminogen deficiency. Blood. 2018;131(12):1301-1310.
15. Pantanowitz L, Bauer K, Tefs K, et al. Ligneous (pseudomembranous) inflamma- tion involving the female genital tract asso- ciated with type-1 plasminogen deficiency. Int J Gynecol Pathol. 2004;23 (3):292-295.
16. Chi AC, Prichard E, Richardson MS, Rasenberger KP, Weathers DR, Neville BW. Pseudomembranous disease (ligneous inflammation) of the female genital tract, peritoneum, gingiva, and paranasal sinuses associated with plasminogen deficiency. Ann Diagn Pathol. 2009;13(2):132-139.
17. Cohen J, Cohen S, Cymberknoh MC, Gross M, Hirshoren N, Shoseyov D. Laryngeal obstruction in congenital plasminogen defi- ciency. Pediatr Pulmonol. 2012;47(9):923- 925.
18. Ciftci E, Ince E, Akar N, Dogru U, Tefs K, Schuster V. Ligneous conjunctivitis, hydro- cephalus, hydrocele, and pulmonary involvement in a child with homozygous type I plasminogen deficiency. Eur J Pediatr. 2003;162(7-8):462-465.
19. Weinzierl MR, Collmann H, Korinth MC, Gilsbach JM, Rohde V. Management of hydrocephalus in children with plasmino- gen deficiency. Eur J Pediatr Surg. 2007;17(2):124-128.
20. Schott D, Dempfle CE, Beck P, et al. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med. 1998;339(23):1679-1686.
21. Martin-Fernandez L, Marco P, Corrales I, et al. The unravelling of the genetic architec- ture of plasminogen deficiency and its rela- tion to thrombotic disease. Sci Rep. 2016;6:39255.
22. Hidayat AA, Riddle PJ. Ligneous conjunctivi- tis. A clinicopathologic study of 17 cases. Ophthalmology. 1987;94(8):949-959.
23. De Cock R, Ficker LA, Dart JG, Garner A, Wright P. Topical heparin in the treatment of ligneous conjunctivitis. Ophthalmology. 1995;102(11):1654-1659.
24. Holland EJ, Chan CC, Kuwabara T, Palestine AG, Rowsey JJ, Nussenblatt RB.
Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis. Am J Ophthalmol. 1989;107(2):160-166.
25. Shimabukuro M, Iwasaki N, Nagae Y, et al. Ligneous conjunctivitis: a case report. Jap J Ophthalmol. 2001;45(4):375-377.
26. Firat T. Ligneous conjunctivitis. Am J Ophthalmol. 1974;78(4):679-688.
27. Sartori MT, Saggiorato G, Pellati D, et al. Contraceptive pills induce an improvement in congenital hypoplasminogenemia in two unrelated patients with ligneous conjunctivi- tis. Thromb Haemost. 2003;89(01):86-91.
28. Fine G, Bauer K, Al-Mohaya M, Woo SB. Successful treatment of ligneous gingivitis with warfarin. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(1):77- 80.
29. Barabino S, Rolando M. Amniotic mem- brane transplantation in a case of ligneous conjunctivitis. Am J Ophthalmol. 2004;137 (4):752-753.
30. Tabbara KF. Prevention of ligneous conjunc- tivitis by topical and subconjunctival fresh frozen plasma. Am J Ophthalmol. 2004;138 (2):299-300.
31. Kizilocak H, Ozdemir N, Dikme G, et al. Treatment of plasminogen deficiency patients with fresh frozen plasma. Pediatr Blood Cancer. 2018;65(2):e26779.
32. Watts P, Suresh P, Mezer E, et al. Effective treatment of ligneous conjunctivitis with topical plasminogen. Am J Ophthalmol. 2002;133(4):451-455.
33. Pons V, Olivera P, Garcia-Consuegra R, et al. Beyond hemostasis: the challenge of treating plasminogen deficiency. A report of three cases. J Thromb Thrombolysis. 2016;41 (3):544-547.
34. Nakar CT, Caputo R, Price FW, et al. Safety & efficacy of human plasma derived plas- minogen ophthalmic drops for treatment of ligneous conjunctivitis: report of phase 2/3 clinical trial. Blood. 2015;126(23):2288.
35. O'Mahony B, Noone D, Giangrande PL, Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia. 2013;19(4):e239-247.
36. Keipert C, Hesse J, Haschberger B, et al. The growing number of hemophilia registries: quantity vs. quality. Clin Pharmacol Ther. 2015;97(5):492-501.
37. Osooli M, Berntorp E. Inhibitors in haemophilia: what have we learned from registries? A systematic review. J Intern Med. 2015;277(1):1-15.
38. European Medicines Agency. Report on Haemophilia Registries; Workshop 8 June 2018; Patient Registries Initiative. [cited September 23, 2019]; Available from: https://www.ema.europa.eu/en/docu- ments/report/report-haemophilia-registries- workshop_en.pdf
39. Gupta S, Acharya S, Roberson C, Lail A, Soucie JM, Shapiro A. Potential of the Community Counts registry to characterize rare bleeding disorders. Haemophilia. 2019;25(6):1045-1050.
40. Konkle BA, Johnsen JM, Wheeler M, et al. Genotypes, phenotypes and whole genome sequence: approaches from the My Life Our Future haemophilia project. Haemophilia. 2018;24 Suppl 6:87-94.
41. Centers for Disease Control and Prevention. Community Counts. [cited September 24, 2019]; Available from: https://www.cdc.gov/ncbddd/hemophilia/c ommunitycounts/data-reports/2018- 9/table-1-patient-characteristics-by-calen- dar.html
42. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615-621.
43. Peyvandi F, Di Michele D, Bolton-Maggs PH, et al. Classification of rare bleeding dis- orders (RBDs) based on the association between coagulant factor activity and clini- cal bleeding severity. J Thromb Haemost. 2012;10(9):1938-1943.
44. European Association for Haemophilia and Allied Disorders. Prospective Rare Bleeding Disorders Database (PRO-RBDD). [cited September 23, 2019]; Available from: http://eahad.org/prospective-rare-bleeding- disorders-database-pro-rbdd/
45. Menegatti M, Palla R, Boscarino M, et al. Minimal factor XIII activity level to prevent major spontaneous bleeds. J Thromb Haemost. 2017;15(9):1728-1736.
46. Iorio A, Keepanasseril A, Foster G, et al. Development of a Web-Accessible Population Pharmacokinetic Service- Hemophilia (WAPPS-Hemo): study proto- col. JMIR Res Protoc. 2016;5(4):e239.
47. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33 (1):4-15.
48. Chitlur M, Sorensen B, Rivard GE, et al. Standardization of thromboelastography: a report from the TEG-ROTEM working group. Haemophilia. 2011;17(3):532-537.
49. van Geffen M, Loof A, Lap P, et al. A novel hemostasis assay for the simultaneous measurement of coagulation and fibrinoly- sis. Hematology. 2011;16(6):327-336.
50. Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediat- ed mechanism. Blood. 2004;103(6):2157- 2161.
51. Ma Q, Ozel AB, Ramdas S, et al. Genetic variants in PLG, LPA, and SIGLEC 14 as well as smoking contribute to plasma plasmino- gen levels. Blood. 2014;124(20):3155-3164.
52. Li JF, Lin Y, Yang YH, et al. Fibrinogen Aalpha Thr312Ala polymorphism specifi- cally contributes to chronic thromboem- bolic pulmonary hypertension by increas- ing fibrin resistance. PLoS One. 2013;8 (7):e69635.
haematologica | 2020; 105(3)
561